The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly's application to get approval for the drug Olumiant, which treats atopic dermatitis in adults, according to an Eli Lilly press announcement.
The FDA has granted experts three more months to assess the data sets which Eli Lilly and Incyte have submitted for Olumiant, or barictinib, which is already approved in the US as an arthritis treatment.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.